Group 1 - The Shanghai Stock Exchange has imposed disciplinary actions on Jiangsu Nuotai Aosaino Biopharmaceutical Co., Ltd. and its responsible persons for serious violations, including false disclosures in the 2021 annual report and fabrication of significant false content in convertible bond issuance documents [1] - The violations are in breach of multiple regulations, including the Securities Law and various rules governing the issuance and trading of corporate bonds and stocks on the Science and Technology Innovation Board [1] - Disciplinary actions include public reprimands for key executives and a three-year disqualification for the actual controller from serving as a director or senior management in listed companies [1] Group 2 - For the year 2024, ST Nuotai's revenue composition is heavily weighted towards the pharmaceutical manufacturing sector, accounting for 99.88% of total revenue, with other businesses making up only 0.12% [2] - As of the latest report, ST Nuotai has a market capitalization of 12.2 billion yuan [2]
上交所对江苏诺泰澳赛诺生物制药股份有限公司及有关责任人予以纪律处分